Literature DB >> 8530925

Diagnosis of inherited metabolic disorders affecting the nervous system.

P D Swanson1.   

Abstract

Knowledge of the molecular causes for genetic diseases that affect the nervous system is rapidly expanding. Especially striking has been the finding in several autosomal dominant neurodegenerative disorders that unstable expansions of trinucleotide repeats are responsible for the genetic disorder and that the length of the repeat can be correlated with the age of onset and the severity of symptoms. Phenotypic heterogeneity in many disorders associated with enzyme deficiencies can often be linked to the amount of residual enzyme activity occurring with different gene mutations. Making a specific diagnosis of a neurological disorder associated with genetically determined metabolic defects requires access to a laboratory that can assist in arranging for appropriate testing to be carried out. In some disorders such as the aminoacidurias diagnostic metabolic studies can be performed in hospital clinical chemistry laboratories. In others, such as the lysosomal storage diseases, a laboratory that carries out special lipid analyses and white blood cell enzyme assays will be necessary. DNA mutational analyses are becoming commercially available for diagnosing many disorders such as mitochondrial diseases and those conditions associated with expanded trinucleotide repeats. It may be necessary to contact individual research laboratories when confronted with a disorder that has been newly discovered or that is very rare. A computerised directory of specialised laboratories that perform disease specific testing for genetic disorders should be useful in choosing the appropriate diagnostic or research laboratory.

Entities:  

Mesh:

Year:  1995        PMID: 8530925      PMCID: PMC1073703          DOI: 10.1136/jnnp.59.5.460

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  109 in total

1.  A study of the caeruloplasmin concentrations found in 75 patients with Wilson's disease, their kinships and various control groups.

Authors:  K Gibbs; J M Walshe
Journal:  Q J Med       Date:  1979-07

2.  Moderate homocysteinemia--a possible risk factor for arteriosclerotic cerebrovascular disease.

Authors:  L E Brattstrom; J E Hardebo; B L Hultberg
Journal:  Stroke       Date:  1984 Nov-Dec       Impact factor: 7.914

3.  X-linked mental retardation: a study of 7 families.

Authors:  P A Jacobs; T W Glover; M Mayer; P Fox; J W Gerrard; H G Dunn; D S Herbst
Journal:  Am J Med Genet       Date:  1980

4.  Difficulties in the neonatal diagnosis of Menkes' kinky hair syndrome--trichopoliodystrophy.

Authors:  T R Gunn; S Macfarlane; L I Phillips
Journal:  Clin Pediatr (Phila)       Date:  1984-09       Impact factor: 1.168

5.  The clinical features and classification of the late onset autosomal dominant cerebellar ataxias. A study of 11 families, including descendants of the 'the Drew family of Walworth'.

Authors:  A E Harding
Journal:  Brain       Date:  1982-03       Impact factor: 13.501

6.  Diagnosis of the fragile X syndrome (Martin-Bell syndrome). Clinical findings in 27 males with the fragile site at Xq28.

Authors:  K B Nielsen
Journal:  J Ment Defic Res       Date:  1983-09

7.  Chronic GM1 gangliosidosis presenting as dystonia: I. Clinical and pathological features.

Authors:  J E Goldman; D Katz; I Rapin; D P Purpura; K Suzuki
Journal:  Ann Neurol       Date:  1981-05       Impact factor: 10.422

8.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.

Authors:  V M Berginer; G Salen; S Shefer
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

9.  Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy.

Authors:  H W Moser; A E Moser; I Singh; B P O'Neill
Journal:  Ann Neurol       Date:  1984-12       Impact factor: 10.422

10.  Heterozygous expression of X-linked mental retardation and X-chromosome marker fra(X)(q27).

Authors:  G Turner; R Brookwell; A Daniel; M Selikowitz; M Zilibowitz
Journal:  N Engl J Med       Date:  1980-09-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.